Pharmaceuticals

Global Kesimpta Market Expected To Reach $6.47 Billion By 2030 With 8.3% CAGR

May 5, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Kesimpta Market Between 2026 And 2030?

The historical period’s growth stemmed from several factors, including the limitations inherent in traditional MS therapies, an observed increase in MS diagnosis rates, significant advancements in monoclonal antibody science, the growing adoption of B-cell targeting by neurologists, and the prevailing demand for more convenient dosing options.

Throughout the forecast period, growth is expected to be fueled by an increasing population with relapsing MS, greater acceptance of home injection therapies, the broadening of treatments to include progressive MS forms, enhanced patient adherence to treatment plans, and a surge in investment within neurology healthcare.

Significant trends anticipated during the forecast period encompass a movement towards B-cell depleting therapies, a growing preference for self-administered MS treatments, an expansion in early MS intervention strategies, the escalating use of targeted immunotherapies, and the increased availability of home-based neurology care.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20126&type=smp

Which Primary Drivers Are Impacting The Kesimpta Market Growth?

The anticipated rise in the incidence of multiple sclerosis (MS) is set to enhance the expansion of the kesimpta market in the coming years. Multiple sclerosis is a long-term autoimmune condition impacting the central nervous system, leading to the deterioration of nerve fibers and resulting in symptoms such as muscle weakness, visual disturbances, and cognitive decline. This growing prevalence of MS is attributed to factors like advanced diagnostic methods, increased public awareness, and more efficient reporting mechanisms. Kesimpta addresses relapsing forms of MS by specifically targeting B-cells, which helps in reducing relapse episodes and slowing the advancement of disability. For example, as reported in August 2025 by Neurologia i Neurochirurgia Polska, a peer-reviewed medical journal from Poland, MS incidence in China is observed to be increasing, with yearly estimates ranging from 0.2 to 0.6 per 100,000 people. Similarly, in Turkey, the MS incidence rate in 2022 was 6.2 per 100,000 people, and in Saudi Arabia, recent projections indicate rising MS incidence rates of between 3 and 5 per 100,000 people annually. Consequently, the increasing occurrence of multiple sclerosis is a significant factor propelling the growth of the kesimpta market.

What Are The Main Segments Within The Kesimpta Market Segment Structure?

The kesimpta market covered in this report is segmented –

1) By Indication: Treatment Of Rhabdomyosarcoma (RMS), Treatment Of Clinically Isolated Syndrome (CIS), Treatment Of Active Secondary Progressive Multiple Sclerosis (SPMS)

2) By Formulation: Injectable formulation, Pre-filled Syringes Or Autoinjectors

3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients

4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals, Specialty Pharmacies, Home Healthcare Providers, Neurology Clinics

Which Trends Are Shaping The Kesimpta Market?

A significant development within the Kesimpta market involves self-administered, targeted B-cell therapy designed for addressing relapsing forms of multiple sclerosis (RMS). This particular therapy from Kesimpta offers an efficient and user-friendly treatment alternative for relapsing forms of multiple sclerosis (RMS), leading to a decrease in relapses and a deceleration of disease progression. Illustratively, in April 2024, Novartis AG, a pharmaceutical company located in Switzerland, disclosed six-year effectiveness data concerning its multiple sclerosis medication, Kesimpta (ofatumumab). This information underscored considerable advantages for individuals with relapsing multiple sclerosis (RMS) who were recently diagnosed and had not yet undergone treatment. The ALITHIOS open-label extension study was the source of these findings, emphasizing the critical role of commencing treatment early in the management of this ongoing ailment.

Who Are The Companies Participating In The Kesimpta Market?

Major companies operating in the kesimpta market are Novartis AG

Get The Full Kesimpta Market Report:

https://www.thebusinessresearchcompany.com/report/kesimpta-global-market-report

Where Is The Kesimpta Market Most Concentrated Geographically?

North America was the largest region in the kesimpta market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kesimpta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Kesimpta Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/kesimpta-global-market-report

Browse Through More Reports Similar to the Global Kesimpta Market 2026, By The Business Research Company

Kefir Market Report 2026

https://www.thebusinessresearchcompany.com/report/kefir-global-market-report

K Beauty Products Market Report 2026

https://www.thebusinessresearchcompany.com/report/k-beauty-products-global-market-report

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795